Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | KLK1 | P06870 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522987 | 0.85 | RECQL (0.43) | PNMTTAAR1CYP3A4 | |
| SCHEMBL2006591 | 0.85 | CSNK2A1 (0.52) | CSNK2A1CSNK2A2CSNK2BCSNK2A3PNMT | |
| SCHEMBL27859143 | 0.83 | CSNK2A1 (0.47) | CSNK2A1CSNK2A2CSNK2BCSNK2A3PNMT | |
| SCHEMBL8772771 | 0.79 | TRPA1 (0.43) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL15047147 | 0.79 | CSNK2A1 (0.47) | CSNK2A1CSNK2A2CSNK2BCSNK2A3PNMT | |
| SCHEMBL30442346 | 0.79 | CYP4F2 (0.40) | PNMTTAAR1CYP3A4 | |
| SCHEMBL5138176 | 0.79 | CSNK2A1 (0.62) | CSNK2A1CSNK2A2CSNK2BCSNK2A3PNMT | |
| SCHEMBL7164454 | 0.79 | CYP4F2 (0.40) | PNMTTAAR1CYP3A4 | |
| SCHEMBL14756787 | 0.77 | ABAT (0.44) | TAAR1LOXL2ABATENPP2 | |
| SCHEMBL12429996 | 0.77 | LOXL2 (0.41) | CSNK2A1PNMTLOXL2ABATENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2015-08-20 | — | — | US | disclosed |
| CN-102105473-B | Tricyclic nitrogen containing compounds and their use as antibacterials | GLAXO GROUP LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-102105473-A | Tricyclic nitrogen containing compounds and their use as antibacterials | GLAXO GROUP LTD | 2011-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | DPYD, UMPS, TYMP | CSNK2A1 3501/4885CSNK2A2 3479/4885CSNK2B 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.